GABELLI & Co INVESTMENT ADVISERS INC. purchased a new position in Enzymotec Ltd (NASDAQ:ENZY) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 191,550 shares of the biotechnology company’s stock, valued at approximately $2,270,000.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. acquired a new stake in shares of Enzymotec in the 3rd quarter worth approximately $107,000. SG Americas Securities LLC acquired a new stake in shares of Enzymotec in the 4th quarter worth approximately $116,000. Osborn Williams & Donohoe LLC acquired a new stake in shares of Enzymotec in the 3rd quarter worth approximately $137,000. State Street Corp grew its holdings in shares of Enzymotec by 1.8% in the 2nd quarter. State Street Corp now owns 20,952 shares of the biotechnology company’s stock worth $169,000 after acquiring an additional 380 shares during the period. Finally, Janus Henderson Group PLC acquired a new stake in shares of Enzymotec in the 2nd quarter worth approximately $2,350,000. Institutional investors and hedge funds own 15.73% of the company’s stock.
A number of equities research analysts recently weighed in on the company. Zacks Investment Research upgraded Enzymotec from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 17th. BidaskClub cut Enzymotec from a “hold” rating to a “sell” rating in a report on Saturday, January 6th. Jefferies Group restated a “hold” rating and issued a $11.50 price target on shares of Enzymotec in a report on Thursday, October 19th. Finally, Wells Fargo & Co upped their price target on Enzymotec from $9.50 to $12.00 and gave the stock a “market perform” rating in a report on Monday, October 30th. One investment analyst has rated the stock with a sell rating and four have given a hold rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $11.75.
Shares of Enzymotec Ltd (NASDAQ:ENZY) opened at $11.85 on Monday. The company has a market capitalization of $277.62, a price-to-earnings ratio of -43.89, a price-to-earnings-growth ratio of 3.19 and a beta of 1.22. Enzymotec Ltd has a fifty-two week low of $6.30 and a fifty-two week high of $12.35.
Enzymotec (NASDAQ:ENZY) last announced its earnings results on Wednesday, November 15th. The biotechnology company reported $0.04 EPS for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.03). Enzymotec had a net margin of 2.32% and a return on equity of 1.24%. research analysts expect that Enzymotec Ltd will post 0.05 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “191,550 Shares in Enzymotec Ltd (ENZY) Purchased by GABELLI & Co INVESTMENT ADVISERS INC.” was published by Stock Observer and is the property of of Stock Observer. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.thestockobserver.com/2018/02/05/191550-shares-in-enzymotec-ltd-enzy-purchased-by-gabelli-co-investment-advisers-inc.html.
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.
Want to see what other hedge funds are holding ENZY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enzymotec Ltd (NASDAQ:ENZY).
Receive News & Ratings for Enzymotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec and related companies with MarketBeat.com's FREE daily email newsletter.